A Systematic Review of Risk Factors for Development, Recurrence, and Progression of Vulvar Intraepithelial Neoplasia
暂无分享,去创建一个
[1] M. Schiffman,et al. Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. , 2021, Journal of lower genital tract disease.
[2] J. Berkhof,et al. Vulvar intraepithelial neoplasia: Incidence and long‐term risk of vulvar squamous cell carcinoma , 2020, International journal of cancer.
[3] M. Schiffman,et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2020, Journal of lower genital tract disease.
[4] D. Huntsman,et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status , 2020, Modern Pathology.
[5] C. Gilks,et al. Vulval squamous cell carcinoma and its precursors , 2020, Histopathology.
[6] A. Taylor,et al. The Impact of Focality and Centricity on Vulvar Intraepithelial Neoplasia on Disease Progression in HIV+ Patients: A 10-Year Retrospective Study , 2019, Dermatology.
[7] I. Vistad,et al. Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review , 2018, International Journal of Gynecologic Cancer.
[8] N. Hacker,et al. Vulvar cancer in high‐income countries: Increasing burden of disease , 2017, International journal of cancer.
[9] M. von Knebel Doeberitz,et al. HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course , 2017, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[10] L. Liao,et al. Epidemiology of vulvar neoplasia in the NIH-AARP Study. , 2017, Gynecologic oncology.
[11] C. Lombardo,et al. The association of pre-treatment HPV subtypes with recurrence of VIN. , 2017, European journal of obstetrics, gynecology, and reproductive biology.
[12] J. McAlpine,et al. p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[13] A. García-Jiménez,et al. Vulvar intraepithelial neoplasia: clinical presentation, management and outcomes in women infected with HIV , 2016, AIDS.
[14] M. Zinna,et al. Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3. , 2014, European review for medical and pharmacological sciences.
[15] S. H. van der Burg,et al. Clinical Characteristics Associated With Development of Recurrence and Progression in Usual-Type Vulvar Intraepithelial Neoplasia , 2013, International Journal of Gynecologic Cancer.
[16] Michael Mueller,et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia , 2013, Journal of gynecologic oncology.
[17] F. Sopracordevole,et al. Imiquimod 5% cream versus cold knife excision for treatment of VIN 2/3: a five-year follow-up. , 2013, European review for medical and pharmacological sciences.
[18] Jubilee Brown,et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. , 2012, Gynecologic oncology.
[19] F. Amant,et al. Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review. , 2012, The journal of sexual medicine.
[20] D. Mutch,et al. Clinical and Pathologic Features of Vulvar Intraepithelial Neoplasia in Premenopausal and Postmenopausal Women , 2011, Journal of lower genital tract disease.
[21] L. Massuger,et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. , 2009, European journal of cancer.
[22] H. Honest,et al. Differentiated-Type Vulval Intraepithelial Neoplasia Has a High-Risk Association With Vulval Squamous Cell Carcinoma , 2008, International Journal of Gynecologic Cancer.
[23] Van Seters. Vulvar Intraepithelial Neoplasia: New concepts and strategy , 2008 .
[24] Christian Dannecker,et al. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. , 2006, Gynecologic oncology.
[25] P. Judson,et al. Trends in the Incidence of Invasive and In Situ Vulvar Carcinoma , 2006, Obstetrics and gynecology.
[26] A. Stewart,et al. Vulvar Intraepithelial Neoplasia: Aspects of the Natural History and Outcome in 405 Women , 2005, Obstetrics and gynecology.
[27] M. Carvalho,et al. Vulvar intraepithelial neoplasia p53 expression, p53 gene mutation and HPV in recurrent/progressive cases. , 2004, The Journal of reproductive medicine.
[28] F. Frizelle,et al. High‐grade vulval intraepithelial neoplasia (VIN 3): a retrospective analysis of patient characteristics, management, outcome and relationship to squamous cell carcinoma of the vulva 1989–1999 , 2002, The Australian & New Zealand journal of obstetrics & gynaecology.
[29] J. Hall,et al. Sexual dysfunction following vulvectomy. , 2000, Gynecologic oncology.
[30] S. Modesitt,et al. Vulvar Intraepithelial Neoplasia III: Occult Cancer and the Impact of Margin Status on Recurrence , 1998, Obstetrics and gynecology.
[31] T. Horn,et al. Prognosis of vulvar dysplasia and carcinoma in situ with special reference to histology and types of human papillomavirus (HPV) , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[32] V. Küppers,et al. Risk factors for recurrent VIN. Role of multifocality and grade of disease. , 1997, The Journal of reproductive medicine.
[33] A. Korn,et al. Vulvar intraepithelial neoplasia in women infected with human immunodeficiency virus-1. , 1996, Gynecologic oncology.
[34] M I Shafi,et al. Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women , 1996, British journal of obstetrics and gynaecology.
[35] J. Junge,et al. Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. , 1995, Gynecologic oncology.
[36] B. Ghiringhello,et al. Biologic behavior of vulvar intraepithelial neoplasia. Histologic and clinical parameters. , 1993, The Journal of reproductive medicine.
[37] J. Bock,et al. Intraepithelial neoplasia in the vulvar region. , 1985, Gynecologic oncology.
[38] C. Holschneider,et al. Vulvar intraepithelial neoplasia: Risk factors for recurrence. , 2018, Gynecologic oncology.
[39] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[40] A. D. de Craen,et al. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. , 2005, Gynecologic oncology.
[41] A. Basta,et al. Intraepithelial neoplasia and early stage vulvar cancer. Epidemiological, clinical and virological observations. , 1999, European journal of gynaecological oncology.